Hi Babba, see below for the original article, Sprifermin is one...

Hi Babba, see below for the original article, Sprifermin is one of them mentioned at last year's Oarsi's CTS.
Yes you are quite right, SubQ much much less onerous than Intra-articular.

SubQ also works all over, every joint simultaneously.

I've edited out the last bit of the below post cos some of the images have vanished (Its like perishable food, it doesn't keep! Weird HC).

---- Originally posted 11 March 2023



https://hotcopper.com.au/threads/the-comparative.7276854/?post_id=66717411



good pal of mine suggested the other day, Hey Mozz....you are off to the best conference in the world in terms of OA. Hands down this is the conference to be seen at. Well why don't you investigate just what's on offer by the other participants? They too have been invited to speak., lets do some prelim investigation to see what and who they are and perhaps how do we rank in amongst the titans? Always good to keep an eye open on competition, this is what I want YOU to do. If you see something that doesn't gel well, that could be a threat, this is the place to articulate, just do it professionally...less mud slinging more deep analysis and research!








Another pal of mine pointed out the simple fact that we are sponsoring this year's meet....ramifications of that?

Well think back to the days of Tanezumab...Pfizer and Lilly sponsored that one back then when they thought they had the holy grail....in fact shouldn't we be looking at all candidates that have either been specially invited (CTS) or in fact are sponsoring the conference of conferences?




_{Who was one of the sponsors for the 2021 meet? When and why do you sponsor such a large and prestigious conference? Isn't it when you have a viable and potential candidate?}



Tonight, at least at high level (Can't be too detailed, don't have the bandwidth - hey, I'm busy packing and wrapping up at work, ...not to mention house work...ugh the house work...), lets take a look at who is presenting what in the CTS !!



DISCLAIMER

Now don't forget I'm not a scientist and I'm not a licenced advisor. You really ought to do your own research and while I've tried to cover these, it really only is a high level look through. These companies and their respective drugs could be more compelling than I'm portraying, no one knows the future and how we or they will go. All we can do is research and make our own assessment.

Lets now do that.




THE COMPETITOR'S GRID

	COMPANY	DRUG	MOZZ NOTES	REFERENCES
	Biosplice	Lorecivivint	Failed Primary, some results showing DMOAD capability.
			They have started a P3 with results due Oct 2023 BUT there is evidence that it may only be able to be used for a	https://www.tandfonline.com/doi/abs/10.1080/13543784.2020.1842357?journalCode=ieid20
			certain segment of the population. Also administration might be problematic as not only is it intra-articular but it must
			be administered in the joint space. To exclude the possibility of 'drug leak' it is administered under ultrasound guidance.	https://pubmed.ncbi.nlm.nih.gov/33096010/
	Grünenthal	RTX - Capstain	Phase three	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1409708/
			Whether it is a result of the degeneration of the fibres or a long-lasting but reversible loss of their functions is a matter of controversy.
			Intra-articular
			Dose dependent
	Novartis	LNA043	What are the warnings for canakinumab?
			Serious and sometimes fatal infections may occur during treatment with canakinumab .
			Part immunosuppressant
			But is intra-articular injection

	Trialspark	Sprifermin		https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-021-02488-w
			Had efficacy in structural addressing cartilage thickness against placebo
			"...intra-articular sprifermin did not likely have any positive effect on symptom alleviation".
			But is intra-articular injection
	Sun Pharma/	MM-II	Early stage, pre Phase 2	https://www.frontiersin.org/articles/10.3389/fbioe.2020.00682/full
	Moebius		Lubrication via liposomals, symptomatic relief only, not addressing underlying
			Limited use with patients with chronic pain, addresses mainly basic symptoms
	Xalud Therapeutics	XT-150	Gene Therapy
			Intraarticular
			Good Efficacy in terms of localised pain relief for 6 months
			Phase 2A done
			Longer term studies required to assess risks
			Supplementation of IL-10, single targeting?
	Genascence	GNSC-001	Early stage - P1 complete
			Gene Therapy
			Addressing IL-1(see also Xalud Therapies above)
	Pacira Biosciences	Exparel	Bupivacaine liposome injectable suspension
			Nerve Blocker
			Non Opioid pain relief
			Not DMOAD
			Like a local anaesthetic
			Specific application - Adductor canal (Thigh region)
		FX201	Gene Therapy
			Intra-articular
			Addressing IL-1(see also Xalud Therapies above)
	Kolon TissueGene	Invossa TG-C	Gene Therapy
			Intra-articular
				https://www.koreabiomed.com/news/articleView.html?idxno=7997
			Note:Efficacy in terms of pain relief and DMOAD connotations. P3 expected to primarily read out Aug 2024 and full read out by Aug 2025.
			Joint swelling and injection site pain has been noted
			"Kolon will have to prove that Invossa can demonstrate meaningful improvements in large-scale U.S. studies. Unlike the local trial, the U.S. trials will also include patients with moderate symptoms (Grade 2), which will affect the trial outcomes".
			"Another critical point is whether Invossa can prove efficacy as a DMOAD. In the local trial, the drug failed to show meaningful structural improvement in damaged cartilage in MRIs in the comparison between the treatment group and the control group. The company will have to demonstrate the drug’s cartilage regeneration effect in the U.S. trials".
			"Kolon will also have to prove a clear benefit that overrides a significant risk of gene therapy, which involves injecting transduced cells".
			Transduced cells are basically foreign infused DNA into cells.
	4P-Pharma/4Moving Biotech	liraglutide	Early stage P1
		4P004	Intra articular
			Early but shows promise?
	Rottapharm Biotech	CR4056	Intra-articular PVA Hydrogel in Knee Osteoarthritis	https://www.researchgate.net/publication/335824717_Efficacy_and_safety_of_the_first-in-class_imidazoline-2_receptor_ligand_CR4056_in_pain_from_knee_osteoarthritis_and_disease_phenotypes_a_randomized_double-blind_placebo-controlled_phase_2_trial
			The primary endpoint was met in males only

RISKS


Intra articular like most (if not all!) of the other 11 candidates above has its downsides compared to a SubQ. They are more painful, they can lead to infections, they have to be administered carefully....and there is risk. Here is an example:

How common is tendon rupture after steroid/non steroid injection?

"A review of 356 cases of tendinopathy reported tendon rupture in 3.5 percent of patient not given steroids and 3.7 percent for those who did receive steroids. Another study also found a three percent incidence of tendon rupture in patients administered injectable steroids".